Compare Cassava Sciences Inc (FLNA) vs NetApp Inc. (NTAP) Price & Performance

FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.

Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.

NetApp (NTAP) trades at $174.58, up 6.5% over the past 24 hours, reflecting strong momentum. The stock exhibits bullish technical signals with moving averages supporting an uptrend, though RSI levels suggest potential overbought conditions. Fundamentally, the company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $2.43 exceeding the $2.27 estimate. Revenue for 2025 reached $6.57 billion, with a net income margin of 18.43% and a high return on equity of 106.73%. Recent news highlights NetApp's strategic focus on AI infrastructure and a dividend payment scheduled for July 2026.

The outlook for NTAP is positive, driven by enterprise AI demand and consistent earnings performance. Investment opportunities include exposure to data storage growth and strong profitability metrics. Key risks involve high valuation multiples, competitive pressures in the tech sector, and sensitivity to macroeconomic trends affecting IT spending. Analyst consensus is mixed, with a price target of $167.45 below the current price, indicating caution despite overall bullish sentiment.